^
    Apply
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/07/2023
    Primary completion :
    07/01/2030
    Completion :
    07/01/2030
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical
    Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (ASC4MORE) (NCT03578367)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    11/22/2018
    Primary completion :
    11/08/2021
    Completion :
    02/27/2025
    ABL1 • BCR
    |
    imatinib • nilotinib • Scemblix (asciminib)
    A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START) (NCT05456191)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/21/2022
    Primary completion :
    03/17/2025
    Completion :
    07/07/2031
    ABL1
    |
    nilotinib • Scemblix (asciminib)
    Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTFreedom) (NCT01784068)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/04/2013
    Primary completion :
    05/31/2016
    Completion :
    01/24/2025
    ABL1 • BCR
    |
    BCR-ABL1 E255K • BCR-ABL1 Y253H
    |
    nilotinib
    Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (NCT01698905)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/20/2012
    Primary completion :
    11/26/2015
    Completion :
    01/19/2025
    ABL1 • BCR
    |
    nilotinib
    Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PInNACLe) (NCT02001818)
    Phase 2
    Australasian Leukaemia and Lymphoma Group
    Completed
    Last update posted :
    08/06/2024
    Initiation :
    04/11/2014
    Primary completion :
    01/07/2022
    Completion :
    01/07/2022
    ABL1 • BCR
    |
    imatinib • nilotinib • ViraferonPeg (peginterferon-α-2b)
    Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel (NCT04449549)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    08/24/2020
    Primary completion :
    04/02/2025
    Completion :
    04/08/2025
    NF1
    |
    paclitaxel • nilotinib
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (NCT05554341)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/10/2024
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    PDGFRA
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • nilotinib
    Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib (NCT01746836)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    01/17/2013
    Primary completion :
    12/31/2030
    Completion :
    12/31/2030
    BCR
    |
    dasatinib • imatinib • Iclusig (ponatinib) • nilotinib
    A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (ASC4FIRST) (NCT04971226)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    10/06/2021
    Primary completion :
    11/28/2023
    Completion :
    01/18/2028
    ABL1 • BCR
    |
    dasatinib • imatinib • nilotinib • bosutinib • Scemblix (asciminib)
    De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE) (NCT03874858)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    03/22/2019
    Primary completion :
    07/31/2026
    Completion :
    12/31/2026
    ABL1 • BCR • TFRC
    |
    nilotinib • Scemblix (asciminib)